VENLO, The Netherlands, November 22 /PRNewswire-FirstCall/ -- QIAGEN GmbH, a wholly-owned subsidiary of QIAGEN N.V. and Osmetech Molecular Diagnostics., a division of Osmetech plc , today announced that they have entered into a distribution agreement.
Pursuant to this agreement, Osmetech will incorporate certain preanalytical consumables and technologies from QIAGEN into Osmetech microarray-based solutions for use in diagnostic and research applications. QIAGEN’s proprietary preanalytical technologies provide unmatched reproducibility and efficiency in molecular diagnostics applications. The distribution agreement emphasizes QIAGEN’s position as the leading provider of preanalytical solutions to the diagnostic industry.
“We are pleased that Osmetech Molecular Diagnostics has selected QIAGEN preanalytical technologies for their eSensor amplification and detection system,” said Dr. Frank Krieg-Schneider, Executive Director Strategic Alliances at QIAGEN. “The Osmetech eSensor Platform represents a very attractive platform for molecular diagnostics. We are pleased to contribute to their success by providing QIAGEN preanalytical solutions which significantly contribute sensitive, robust and reliable nucleic acid testing.”
“Osmetech is pleased to enter into this relationship with QIAGEN”, said Bruce A. Huebner, President of Osmetech Molecular Diagnostics. “QIAGEN’s reputation for providing quality preanalytical solutions is well established in the marketplace. This step is in line with Osmetech Molecular Diagnostic’s goal to provide a quality molecular assay solution to its customers”.
About QIAGEN:
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, China, Sweden, and the Netherlands believes it is the world’s leading provider of innovative enabling technologies and products for molecular diagnostics solutions and preanalytical sample preparation for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN’s products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs more than 1,500 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.
About OSMETECH:
Osmetech Molecular Diagnostics is a division of Osmetech plc, a fast developing international diagnostics business with U.S operations located near Atlanta, Boston and Pasadena, and is focused on providing practical, cost-effective technologies and tools that enable a broad range of hospitals and laboratories to offer molecular diagnostic services for improved patient care. The eSensor(R) DNA Detection System is designed to meet the demands of clinical laboratories that need access to molecular testing capabilities in an easy-to-use format combining universal platform design and advanced micro-array based electrochemical detection technology. The OPTI GENE(TM) System is a rapid and flexible PCR platform enabling genetic analyses in hospital and clinical research laboratories. Further information on OSMETECH can be found at www.osmetech.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN’s, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Qiagen N.V.
CONTACT: Contacts: Peer M. Schatz, Chief Executive Officer, QIAGEN N.V.,+49-2103-29-11702, e-mail: peer.schatz@QIAGEN.com; Dr. Solveigh Mahler,Director Investor Relations, QIAGEN N.V., +49-2103-29-11710, e-mail:solveigh.maehler@QIAGEN.com; Dr. Frank Krieg-Schneider, Executive DirectorStrategic Alliances, QIAGEN GmbH, +49-2103-29-16266, e-mail:frank.krieg-schneider@QIAGEN.com
